Uveitis Treatment Market Research Report, Share, and Forecast to 2025Posted by rekha on October 9th, 2019 Precision Business Insights (PBI) in its report titled “Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period from 2019 to 2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. The uveitis treatment market size was accounted for US$ 496.8 Mn in 2018 and anticipated to grow at prominent growth rate over the forecast timeframe. The uveitis treatment market exhibits high potential due to surge in the prevalence and incidence of uveitis around the globe. For instance, according to Occular Immunology and Uveitis Foundation, the prevalence of uveitis is 38 cases per 100,000 population and the incidence is 15 cases per 100,000 population. Currently, more than 2.3 Mn people are effected with uveitis around the globe. Moreover, increase in the R&D for the development of newer therapeutics, government schemes to rise in awareness about the ocular diseases, development in healthcare infrastructure, and strong product pipeline are anticipated to propel the uveitis treatment market over the forecast years. However, adverse effects associated with drugs, lack of disease awareness among the population in underdeveloped countries, high cost of products are the factors limit the growth of uveitis treatment market over the forecast timeframe Uveitis treatment market segmented on the basis of drug class, disease type, cause, distribution channels, and region, For more sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15626 Monoclonal Antibodies Segment Expected to Dominate the Market Based on drug class, the uveitis market is segmented as immunosuppressant, corticosteroids, monoclonal antibodies, antibiotics, antivirals, antifungal, and others. Monoclonal Antibodies dominate the global uveitis treatment market over the forecast years owing to increase in R&D activities for the development and launch of newer drugs into market. For instance, in June 2018, AbbVie and Eisai launched the Humira (Adalimumab), a human anti-TNF-α monoclonal antibody used in the treatment of uveitis. Moreover, Corticosteroids have lucrative opportunities over the forecast period owing to low cost and better availability of the products in the market. North America Accounts for Major Revenue Share for Uveitis Treatment Market Precision Business Insights (PBI) uveitis treatment market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, North America uveitis treatment market expected to retain its dominance throughout the forecast period due to sure in the prevalence of uveitis in U.S. for instance, according to Occular Immunology and Uveitis Foundation, approximately 109,000 people effected with uveitis in U.S. and approximately 43,000 new cases diagnosed with uveitis each year. Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2018. Strategic Acquisition Play Vital Role in Uveitis Treatment Market Some of the key players are actively promoting their products by adopting various market strategy which sheers their footprint in the global market. For instance, in October 2018, EyePoint Pharmaceuticals received FDA approval for YUTIQ (Fluocinolone acetonide intravitreal implant) used in the treatment of chronic non-infectious uveitis Some of the key players in the uveitis market mentioned in this report are AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Eyepoint Phramaceuticals, Inc. (U.S.), Eisai Co., Ltd. (U.S.), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan) Detailed Segmentation
By Drug Class Type o Corticosteroids o Immunosuppressant o Monoclonal antibodies o Antibiotics o Antivirals o Antifungal o Others By Disease Type o Anterior Uveitis o Posterior Uveitis o Intermediate Uveitis o Panuveitis By Cause o Infectious Uveitis o Non-infectious Uveitis By Distribution Channel o Retail Pharmacies o Online Pharmacies o Hospital Pharmacies
Geography
o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa
For more information: https://www.precisionbusinessinsights.com/market-reports/global-uveitis-treatment-market/ Like it? Share it! More by this author |